Sign In
Buy SILO
$4.19
-0.0600 (-1.41%)
At Close: Jul 31, 2026
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
08:45am, Tuesday, 14'th May 2024
Silo's SP-26 currently in development utilizes ketamine as primary therapeutic agent Silo's SP-26 currently in development utilizes ketamine as primary therapeutic agent
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
08:15am, Tuesday, 23'rd Apr 2024
Intranasal Delivery of SPC-15 shows rapid and effective drug exposure for PTSD Therapy SARASOTA, FL, April 23, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company�
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic
08:11am, Wednesday, 10'th Apr 2024
SPC-14 shows cognitive and stress reduction benefits in preclinical models SARASOTA, FL, April 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a deve
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
07:15am, Monday, 18'th Mar 2024
Silo reports positive stability of SP-26 for time-release and dosage control SARASOTA, FL, March 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a deve
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
08:25am, Wednesday, 28'th Feb 2024
All animal subjects tolerated maximum dosing Once-per-day human intranasal dosing regimen determined for clinical evaluation SARASOTA, FL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq:
Silo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
08:45am, Wednesday, 14'th Feb 2024
Initial indications target fibromyalgia and chronic pain Loaded and encapsulated drug maintains structural stability as implantable treatment SARASOTA, FL, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharm
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
10:00am, Thursday, 01'st Feb 2024
Preparing Pre-Investigational New Drug Application for lead drug program SPC-15 Company plans to pursue FDA streamlined 505(b)(2) pathway for clinical drug development SARASOTA, FL, Feb. 01, 2024 (GLO
Silo Pharma Announces Positive Results in Alzheimer's Disease Study
08:55am, Wednesday, 24'th Jan 2024
Preclinical study shows SPC-14's effectiveness against LH (luteinizing hormone) stress, helplessness, and anxiety. SARASOTA, FL, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (�
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD
08:55am, Thursday, 04'th Jan 2024
Final validation report expected in first quarter 2024 ENGLEWOOD CLIFFS, NJ, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stag
Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
08:25am, Thursday, 28'th Dec 2023
Silo dosage and time-release formulation aim for potential first at-home Ketamine therapeutic SARASOTA, FL, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Co
MedSpray's patented nose-to-brain intranasal technology selected for SPC-15 drug delivery Exclusivity covers multiple indications including anxiety disorders, Alzheimer's disease, and anorexia ENGLEWO
Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD
08:11am, Wednesday, 08'th Nov 2023
Study to determine therapeutic relevant dose range and pharmacokinetic to be used for first-in-human trial Study to determine therapeutic relevant dose range and pharmacokinetic to be used for first-i
Silo Pharma's SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis
08:11am, Monday, 16'th Oct 2023
Human tissue study assessed SPU-21's efficiency, optimization, and binding affinity ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a de
Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD
08:35am, Wednesday, 11'th Oct 2023
Study to test effectiveness of Instructional System Designs (ISD) model for Intranasal SPC-15 ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company�
Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA
08:28am, Wednesday, 20'th Sep 2023
Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Compa
